Scarlet Therapeutics
PrivateLast Round
Seed
May 7, 2026
Total Funding Raised
$4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Scarlet Therapeutics operates in Healthcare & Life Sciences and is based in Bristol. Its latest recorded funding round was a Seed round in May 2026.
Scarlet Therapeutics is a biotechnology company developing a platform for generating therapeutic red blood cell (tRBC) therapies to treat rare metabolic diseases, cancer, and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Scarlet Therapeutics Comparables
Compare Scarlet Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Safi Biotherapeutics | 76% | |
| Garuda | 60% | |
| Anokion | 50% |
For institutional investors. Book with your work email.
Scarlet Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 7, 2026 | ||||
| Pre Seed | May 23, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Scarlet Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oshen Holdings SA | Seed |
| SCVC | Seed |
| Meltwind Advisory | Pre Seed |
| Daft Capital | Seed |
| Science Creates Ventures | Seed, Pre Seed |
| Eos Advisory | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 7, 2026
$4M round led by Eos Advisory.
- Nov 9, 2025
Monthly visitors grew 108% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 29, 2026
On Sep 29th '26, Scarlet Therapeutics Limited was developing a biologics platform that engineers universal red blood cells (RBCs) into long-acting medicines, initially for metabolic disease.
- partners_withSep 23, 2026
Scarlet Therapeutics Limited partners with Northwestern University.
- partners_withSep 23, 2026
Scarlet Therapeutics Limited plans to coordinate the engineered red blood cell project with Bristol Old Vic Company, Northwestern University, and Unicorn Biotechnologies to develop cells that respond to physiological signals, as reported on Sep 23rd '26.
- partners_withSep 23, 2026
Scarlet Therapeutics Limited is to coordinate with Unicorn Biotechnologies Ltd. on a project to generate red blood cells that sense and respond to physiological stimuli such as hypoxia.
- is_developingSep 23, 2026
Scarlet Therapeutics Limited entered into an agreement with DARPA to advance development of smart red blood cells and will lead a multidisciplinary consortium in a program worth up to USD $14 million, announced in United Kingdom on Sep 23rd '26.
For institutional investors. Book with your work email.
Scarlet Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Scarlet Therapeutics's valuation, stock price, and market status.
Is Scarlet Therapeutics a public or private company?
Scarlet Therapeutics is a private company.
What is the current stock price of Scarlet Therapeutics?
Scarlet Therapeutics is a private company, so its shares have no public market price. Caplight tracks Scarlet Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Scarlet Therapeutics worth (valuation)?
Valuation information for Scarlet Therapeutics is not publicly available.
Can I buy Scarlet Therapeutics stock?
Scarlet Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Scarlet Therapeutics's last funding round?
Scarlet Therapeutics's most recent funding round was Seed on May 7, 2026.
Who are the main investors in Scarlet Therapeutics?
Key investors in Scarlet Therapeutics include Meltwind Advisory, Science Creates Ventures, Eos Advisory.
Will Scarlet Therapeutics IPO soon?
No public IPO plans have been announced for Scarlet Therapeutics.
How can I track Scarlet Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Scarlet Therapeutics's shares on secondary markets.